Skip to content

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF)

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
author avatar
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
See Full Bio
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Similar Posts

Updated Guideline for the Management of Lipids and Cholesterol

The American College of Cardiology (ACC), the American Heart Association, and nine other leading medical associations today released an updated guideline for the treatment of...

more »Updated Guideline for the Management of Lipids and Cholesterol

RMC prevents pancreatic cancer

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they develop into tumors. The use of a...

more »RMC prevents pancreatic cancer

Grünenthal initiates Phase I study with new NaV1.8 inhibitor for pain

The pharmaceutical company Grünenthal has begun the first Phase I study with its own orally available inhibitor of the voltage-gated sodium channel NaV1.8. The first healthy volunteers have already been enrolled...

more »Grünenthal initiates Phase I study with new NaV1.8 inhibitor for pain